<DOC>
	<DOC>NCT00382096</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of a fixed combination of vildagliptin and metformin in lowering blood glucose in patients with type 2 diabetes</brief_summary>
	<brief_title>Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male or female (nonfertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes Diagnosis of T2DM for at least 4 weeks prior to study entry Age 18 78 years inclusive Body mass index (BMI) of 22 40 kg/m2 HbA1c: 7.5 11% inclusive FPG &lt;270 mg/dL (15 mmol/L) Exclusion Criteria Pregnant or lactating female A history of type 1 diabetes Evidence of significant diabetic complications Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin</keyword>
	<keyword>hemoglobin A1c</keyword>
</DOC>